What is Edgewise Therapeutics, Inc.'s earnings per share (EPS)?

Edgewise Therapeutics, Inc. (EWTX) reported diluted earnings per share of $-1.63 for fiscal year 2025. This represents a -12.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Edgewise Therapeutics, Inc. Financials

EWTX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Edgewise Therapeutics, Inc. (EWTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Edgewise Therapeutics, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.86x

For every $1 of reported earnings, Edgewise Therapeutics, Inc. generates $0.86 in operating cash flow (-$143.8M OCF vs -$167.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$189.1M

YoY-20.8%

Edgewise Therapeutics, Inc.'s EBITDA was -$189.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.8% from the prior year.

Net Income

-$167.8M

YoY-25.4%

Edgewise Therapeutics, Inc. reported -$167.8M in net income in fiscal year 2025. This represents a decrease of 25.4% from the prior year.

EPS (Diluted)

$-1.63

YoY-12.4%

Edgewise Therapeutics, Inc. earned $-1.63 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 12.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$144.1M

YoY-30.6%

Edgewise Therapeutics, Inc. generated -$144.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 30.6% from the prior year.

Cash & Debt

$61.1M

YoY+46.8%

5Y CAGR-10.2%

Edgewise Therapeutics, Inc. held $61.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

106M

YoY+12.0%

Edgewise Therapeutics, Inc. had 106M shares outstanding in fiscal year 2025. This represents an increase of 12.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-32.1%

YoY-3.0pp

Edgewise Therapeutics, Inc.'s ROE was -32.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 3.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$151.4M

YoY+19.2%

5Y CAGR+58.8%

Edgewise Therapeutics, Inc. invested $151.4M in research and development in fiscal year 2025. This represents an increase of 19.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$256K

YoY-80.5%

5Y CAGR+4.7%

Edgewise Therapeutics, Inc. invested $256K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 80.5% from the prior year.

EWTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$151.4M+19.2%	$127.0M+39.7%	$90.9M+68.2%	$54.0M+67.9%	$32.2M+114.8%	$15.0M
SG&A Expenses	$40.0M+25.6%	$31.9M+35.9%	$23.5M+33.1%	$17.6M+59.9%	$11.0M+399.1%	$2.2M
Operating Income	-$191.4M-20.5%	-$158.8M-38.9%	-$114.4M-59.6%	-$71.7M-65.8%	-$43.2M-151.4%	-$17.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$4K+33.3%	$3K-25.0%	$4K	$0	$0	N/A
Net Income	-$167.8M-25.4%	-$133.8M-33.6%	-$100.2M-48.1%	-$67.6M-58.0%	-$42.8M-150.0%	-$17.1M
EPS (Diluted)	$-1.63-12.4%	$-1.45+7.6%	$-1.57-24.6%	$-1.26-10.5%	$-1.14	$-23.17

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$37.5M+11.7%	$33.6M-8.7%	$36.8M	N/A	$32.2M+5.0%	$30.7M+10.8%	$27.7M
SG&A Expenses	N/A	$9.4M+3.6%	$9.1M-1.6%	$9.2M	N/A	$8.2M+10.5%	$7.4M+5.2%	$7.1M
Operating Income	N/A	-$46.9M-10.0%	-$42.6M+7.3%	-$46.0M	N/A	-$40.4M-6.1%	-$38.1M-9.7%	-$34.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$40.7M-12.6%	-$36.1M+11.5%	-$40.8M	N/A	-$34.1M-8.4%	-$31.5M-10.4%	-$28.5M
EPS (Diluted)	N/A	$-0.39-14.7%	$-0.34+20.9%	$-0.43	N/A	$-0.36-5.9%	$-0.34-3.0%	$-0.33

EWTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$552.6M+13.5%	$486.8M+43.2%	$340.0M-7.4%	$367.1M+28.7%	$285.2M+117.5%	$131.1M
Current Assets	$543.4M+14.3%	$475.5M+45.4%	$327.0M-8.4%	$357.0M+25.8%	$283.8M+118.9%	$129.6M
Cash & Equivalents	$61.1M+46.8%	$41.7M-51.6%	$86.1M+291.5%	$22.0M+41.3%	$15.6M-85.2%	$104.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$30.3M+9.9%	$27.6M+30.2%	$21.2M+4.0%	$20.4M+87.9%	$10.8M-93.4%	$164.6M
Current Liabilities	$27.4M+14.7%	$23.9M+42.3%	$16.8M+1.1%	$16.6M+57.6%	$10.5M+142.3%	$4.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$522.3M+13.7%	$459.2M+44.0%	$318.8M-8.0%	$346.7M+26.4%	$274.4M+921.0%	-$33.4M
Retained Earnings	-$546.4M-44.3%	-$378.6M-54.7%	-$244.8M-69.3%	-$144.6M-87.9%	-$77.0M-125.4%	-$34.1M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$552.6M-5.3%	$583.5M-4.9%	$613.3M+35.0%	$454.4M-6.7%	$486.8M-4.8%	$511.3M-3.8%	$531.6M-4.0%	$553.8M
Current Assets	$543.4M-5.3%	$573.9M-4.9%	$603.3M+36.1%	$443.2M-6.8%	$475.5M-4.8%	$499.4M-3.9%	$519.4M-4.1%	$541.4M
Cash & Equivalents	$61.1M+32.9%	$46.0M+6.0%	$43.4M-13.1%	$49.9M+19.8%	$41.7M-7.0%	$44.8M+3.0%	$43.5M+43.7%	$30.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$30.3M+22.3%	$24.8M+2.3%	$24.3M-1.7%	$24.7M-10.6%	$27.6M+23.2%	$22.4M+5.8%	$21.2M+12.2%	$18.9M
Current Liabilities	$27.4M+26.4%	$21.6M+3.6%	$20.9M-1.0%	$21.1M-11.5%	$23.9M+25.9%	$19.0M+10.4%	$17.2M+17.6%	$14.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$522.3M-6.5%	$558.6M-5.2%	$589.1M+37.1%	$429.7M-6.4%	$459.2M-6.1%	$488.9M-4.2%	$510.5M-4.6%	$534.9M
Retained Earnings	-$546.4M-10.1%	-$496.2M-8.9%	-$455.5M-8.6%	-$419.4M-10.8%	-$378.6M-11.7%	-$338.9M-11.2%	-$304.8M-11.5%	-$273.3M

EWTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$143.8M-31.9%	-$109.0M-18.6%	-$91.9M-74.7%	-$52.6M-57.1%	-$33.5M-129.0%	-$14.6M
Capital Expenditures	$256K-80.5%	$1.3M-77.2%	$5.7M+3.6%	$5.5M+730.2%	$668K+229.1%	$203K
Free Cash Flow	-$144.1M-30.6%	-$110.3M-12.9%	-$97.7M-67.9%	-$58.2M-70.2%	-$34.2M-130.3%	-$14.8M
Investing Cash Flow	-$32.8M+82.2%	-$184.7M-279.5%	$102.9M+245.8%	-$70.6M+70.9%	-$242.2M-893.5%	-$24.4M
Financing Cash Flow	$196.1M-21.3%	$249.3M+368.8%	$53.2M-59.0%	$129.6M-30.4%	$186.4M+55.0%	$120.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$38.6M-11.0%	-$34.8M-6.7%	-$32.6M+14.0%	-$37.9M-40.5%	-$27.0M+1.5%	-$27.4M-4.9%	-$26.1M+8.7%	-$28.6M
Capital Expenditures	$73K	N/A	N/A	N/A	$274K-47.3%	$520K+135.3%	$221K-25.6%	$297K
Free Cash Flow	-$38.7M	N/A	N/A	N/A	-$27.2M+2.4%	-$27.9M-6.0%	-$26.3M+8.9%	-$28.9M
Investing Cash Flow	$49.8M+39.3%	$35.7M+122.0%	-$162.2M-469.4%	$43.9M+109.8%	$20.9M-17.5%	$25.4M-32.1%	$37.4M+113.9%	-$268.3M
Financing Cash Flow	$4.0M+139.6%	$1.7M-99.1%	$188.2M+8367.4%	$2.2M-23.2%	$2.9M-13.1%	$3.3M+70.7%	$2.0M-99.2%	$241.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

EWTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-32.1%-3.0pp	-29.1%+2.3pp	-31.4%-11.9pp	-19.5%-3.9pp	-15.6%	N/A
Return on Assets	-30.4%-2.9pp	-27.5%+2.0pp	-29.5%-11.0pp	-18.4%-3.4pp	-15.0%-2.0pp	-13.1%
Current Ratio	19.85-0.1	19.93+0.4	19.50-2.0	21.53-5.4	26.97-2.9	29.86
Debt-to-Equity	0.060.0	0.060.0	0.070.0	0.06+0.0	0.04+5.0	-4.92
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-7.3%-1.2pp	-6.1%+3.4pp	-9.5%	N/A	-7.0%-0.8pp	-6.2%-0.8pp	-5.3%
Return on Assets	N/A	-7.0%-1.1pp	-5.9%+3.1pp	-9.0%	N/A	-6.7%-0.8pp	-5.9%-0.8pp	-5.1%
Current Ratio	19.85-6.7	26.51-2.4	28.87+7.9	20.99+1.1	19.93-6.4	26.35-3.9	30.24-6.8	37.08
Debt-to-Equity	0.06+0.0	0.040.0	0.04-0.0	0.060.0	0.06+0.0	0.050.0	0.040.0	0.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Viridian Therapeutics Inc VRDN

$2.0B

Vera Therapeutics, Inc. VERA

$2.9B

Aurinia Pharmace AUPH

$2.1B

Ardelyx ARDX

$1.5B

Pharvaris N.V. PHVS

$1.9B

Frequently Asked Questions

Is Edgewise Therapeutics, Inc. profitable?

No, Edgewise Therapeutics, Inc. (EWTX) reported a net income of -$167.8M in fiscal year 2025.

What is Edgewise Therapeutics, Inc.'s EBITDA?

Edgewise Therapeutics, Inc. (EWTX) had EBITDA of -$189.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Edgewise Therapeutics, Inc.'s return on equity (ROE)?

Edgewise Therapeutics, Inc. (EWTX) has a return on equity of -32.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Edgewise Therapeutics, Inc.'s free cash flow?

Edgewise Therapeutics, Inc. (EWTX) generated -$144.1M in free cash flow during fiscal year 2025. This represents a -30.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Edgewise Therapeutics, Inc.'s operating cash flow?

Edgewise Therapeutics, Inc. (EWTX) generated -$143.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Edgewise Therapeutics, Inc.'s total assets?

Edgewise Therapeutics, Inc. (EWTX) had $552.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Edgewise Therapeutics, Inc.'s capital expenditures?

Edgewise Therapeutics, Inc. (EWTX) invested $256K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Edgewise Therapeutics, Inc. spend on research and development?

Edgewise Therapeutics, Inc. (EWTX) invested $151.4M in research and development during fiscal year 2025.

How many shares does Edgewise Therapeutics, Inc. have outstanding?

Edgewise Therapeutics, Inc. (EWTX) had 106M shares outstanding as of fiscal year 2025.

What is Edgewise Therapeutics, Inc.'s current ratio?

Edgewise Therapeutics, Inc. (EWTX) had a current ratio of 19.85 as of fiscal year 2025, which is generally considered healthy.

What is Edgewise Therapeutics, Inc.'s debt-to-equity ratio?

Edgewise Therapeutics, Inc. (EWTX) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Edgewise Therapeutics, Inc.'s return on assets (ROA)?

Edgewise Therapeutics, Inc. (EWTX) had a return on assets of -30.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Edgewise Therapeutics, Inc.'s cash runway?

Based on fiscal year 2025 data, Edgewise Therapeutics, Inc. (EWTX) had $61.1M in cash against an annual operating cash burn of $143.8M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Edgewise Therapeutics, Inc.'s Piotroski F-Score?

Edgewise Therapeutics, Inc. (EWTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Edgewise Therapeutics, Inc.'s earnings high quality?

Edgewise Therapeutics, Inc. (EWTX) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.